Exploring the Use of a Predictive Tool for Methotrexate Clearance sponsored by BTG Specialty Pharmaceuticals

This episode is sponsored by BTG Speciality Pharmaceuticals. BTG provides rescue medicines typically used in emergency rooms and intensive care units to treat patients for whom there are limited treatment options. They are dedicated to delivering quality medicines that make a real difference to patients and their families through the development, manufacture, and commercialization of pharmaceutical products. Their current portfolio of antidotes counteracts certain snake venoms and the toxicity associated with some heart and cancer medications. Their drug, Voraxaze, is for high-dose methotrexate toxicity. Brooke Bernhardt, PharmD, MS, BCOP, BCPPS is an Assistant Professor in the Department of Pediatrics, Section of Pediatric Hematology/Oncology at Baylor College of Medicine in Houston, Texas and the Director of Pharmacy for Global HOPE (Hematology/Oncology Pediatric Excellence). Her research interests include improving pharmacy practice globally with a focus in Sub-Saharan Africa, ethical and practical strategies for managing and mitigating medication shortages, health disparities in pediatric oncology, and the role of pharmacogenomics in pediatric oncology. She has a particular interest in antimetabolite disposition and the impact of host-related factors on toxicity and clinical outcomes.